August 29, 2006 – SGX Pharma discontinued trials of its leukemia drug Troxatyl because it did not provide a benefit; ViroPharma said its hepatitis C therapy was effective against hepatitis C; CytRx rose after receiving a $24.5 million grant to underwrite research costs for its ALS drug; StemCells licensed technology to Stem Cell Therapeutics; GenVec received a $430,000 grant to develop adenovector-based vaccines; and Endo and Teva agreed to stop producing generic versions of OxyContin. The Centient Biotech 200™ climbed 27 points to 3748.10, the highest point since early May and a rise of .73%. More details...
